ClinicalTrials.gov
ClinicalTrials.gov Menu

Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02073838
Recruitment Status : Recruiting
First Posted : February 27, 2014
Last Update Posted : March 7, 2017
Sponsor:
Information provided by (Responsible Party):
Sarit Assouline, Jewish General Hospital

Brief Summary:
This is a research study of ribavirin which will be given in combination with vismodegib and/or decitabine. The purpose of this study is to see if patients respond to treatment when ribavirin is given with vismodegib alone or in combination with decitabine.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Ribavirin Drug: Vismodegib Drug: Decitabine Phase 2

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-center, Open Label, Randomized Study of Ribavirin and Hedgehog Inhibitor With or Without Decitabine in Acute Myeloid Leukemia (AML)
Study Start Date : May 2015
Estimated Primary Completion Date : June 2018
Estimated Study Completion Date : June 2018


Arm Intervention/treatment
Experimental: Ribavirin, vismodegib, decitabine
Decitabine 20mg/m2 IV QD days -7 to -3 for cycle 1. Ribavirin 1400mg BID and vismodegib 150mg QD starting on day 1. On subsequent cycles, decitabine will be administered on days 1 to 5.
Drug: Ribavirin
Drug: Vismodegib
Drug: Decitabine
Experimental: Ribavirin, vismodegib
Ribavirin 1400mg BID, vismodegib 150mg QD
Drug: Ribavirin
Drug: Decitabine



Primary Outcome Measures :
  1. Efficacy will be measured by overall response rate (ORR). [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]

Secondary Outcome Measures :
  1. Time to response [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
  2. Duration of response [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
  3. One year survival [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
  4. Overall survival [ Time Frame: Measured up to 3 years after the last subject has enrolled in the study. ]
  5. Hematologic improvement defined by the number of individual, positively affected cell lines (erythroid, neutrophil and platelet cells) per patient. [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
  6. Number of participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]
  7. Changes in eIF4E expression, localization, and signalling pathways (measured by immuno-histochemical analysis, PCR or western blot) and correlating with each patient's overall response. [ Time Frame: Measured up to 2 years after the last subject has enrolled in the study. ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA

  1. Patients with AML M4 or M5 FAB subtype or high eIF4E are eligible.
  2. All patients must have failed primary therapy (defined as two induction chemotherapies), must have relapsed, or must not be suitable candidates for intensive induction chemotherapy.
  3. Patients who have a dry aspirate or extramedullary disease only are eligible for this study if they have a pre-treatment marrow or tissue biopsy demonstrating AML M4 or M5 subtype or high eIF4E.
  4. ECOG performance status 0, 1, 2.
  5. Life expectancy>4 weeks.
  6. Age is > 18 years.
  7. Female patients of childbearing potential (FCBP) is defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy, or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months). In addition, women under the age of 55 years must have a serum follicle stimulating hormone (FSH) level > 40IU/L to confirm menopause.

    FCBP must have a negative serum (beta-HCG) pregnancy test (minimum sensitivity 25 IU/L of equivalent units of HCG) within 7 days of starting treatment and must not be breastfeeding. Men and females of childbearing potential must agree to use two effective means of contraception, with one method being highly effective and the other method being either highly effective or less effective as listed below throughout the study and for at least 24 months after completion of protocol.

    An effective means of contraception includes the following:

    i. Male condoms with spermicide ii. Hormonal methods of contraception including combined oral contraception pills, vaginal ring, injectables, implants, and intrauterine devices (IUDs).

    iii. Nonhormonal IUDs iv. Tubal ligation v. Vasectomy vi. Complete Abstinence

    A less effective means of contraception includes the following:

    i. Diaphragm with spermicide ii. Vaginal sponge iii. Male condom without spermicide iv. Progestin only pills by females of childbearing potential or male subject's FCBP partners v. Female condom (a male and female condom must not be used together)

    Male subjects must not donate semen while on study and during 24 months after treatment discontinuation.

  8. Adequate renal and hepatic function: serum creatinine < 1.5 x ULN; AST or ALT < 2.5 x ULN (or < 5 x ULN if liver involvement with leukemia); serum bilirubin < 1.5 x ULN
  9. Provide written consent after the investigational nature, study design, risks and benefits of the study have been explained.
  10. Accessible for treatment and follow up.

EXCLUSION CRITERIA

  1. Patients with impaired ribavirin uptake. As tested in the central laboratory.
  2. Uncontrolled central nervous system involvement by AML.
  3. Active cardiovascular disease as defined by New York Heart Association (NYHA) class III-IV categorization.
  4. Patients with hemoglobinopathies which may affect their ability to tolerate ribavirin.
  5. Intercurrent illness or medical condition precluding safe administration of the planned protocol treatment or required follow-up.
  6. Received any previous therapy for AML within 28 days prior to the study entry. Hydrea is permitted for the treatment of leukocytosis but must be stopped prior to starting study drugs.
  7. Female patients who are pregnant or breastfeeding.
  8. Concurrent treatment with other anti-cancer therapy except adjuvant antihormonal agents for breast cancer or for limited stage prostate cancer.
  9. Known infection with HIV.
  10. History of other active malignancy. Subjects who have been disease-free for 2 year or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
  11. FAB AML M1, 2, 6, 7 will be excluded if they do not have high eIF4E expression. AML M3 is always excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02073838


Contacts
Contact: Eftihia Cocolakis, PhD 15143408222 ext 3628 ecocolakis@jgh.mcgill.ca

Locations
Canada, Quebec
Jewish General Hospital Recruiting
Montreal, Quebec, Canada, H3T1E2
Contact: Eftihia Cocolakis, PhD    5143408222 ext 3628    ecocolakis@jgh.mcgill.ca   
Principal Investigator: Sarit Assouline, MD         
Sponsors and Collaborators
Sarit Assouline
Investigators
Principal Investigator: Sarit Assouline, MD Jewish General Hospital

Responsible Party: Sarit Assouline, Hematologist-oncologist, Jewish General Hospital
ClinicalTrials.gov Identifier: NCT02073838     History of Changes
Other Study ID Numbers: Ribavirin=005
First Posted: February 27, 2014    Key Record Dates
Last Update Posted: March 7, 2017
Last Verified: March 2017

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Ribavirin
Decitabine
Azacitidine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antiviral Agents
Anti-Infective Agents
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors